Commons2nd reading

Age-Related Macular Degeneration Bill

To make provision for the treatment of age-related macular degeneration; and for connected purposes.

Originating House

House of Commons

Parliament last updated

1 November 2007

In Plain English

AI-generated

May contain errors — check source documents for definitive information.

This bill would set out provisions for the treatment of age-related macular degeneration (AMD) and related purposes. It aims to create a legal framework to support the delivery of AMD treatment and related services. It reflects the intention to improve access to care for people affected by AMD.

Key Points

Aims to make provision for the treatment of age-related macular degeneration (AMD) and related purposes.
Seeks to establish a statutory framework to support AMD treatment delivery and related activities.
Originated in the House of Commons and is currently at the 2nd reading in the Commons.
An amendment paper has been published to accompany the bill’s progression.

Progress

Currently at the second reading in the House of Commons, having originated there. An amendment paper has been published accompanying the bill.

Who is affected?

People with age-related macular degenerationTheir families and carersHealthcare professionals and NHS services involved in AMD treatment

Generated 21 February 2026

Bill Stages

1st readingCommons

16 Jan 2007

2nd readingCommons

Committee stageCommons

Report stageCommons

3rd readingCommons

1st readingLords

2nd readingLords

Committee stageLords

Report stageLords

3rd readingLords

Royal Assent

Updates & Documents

Documents (1)

Marshalled List of Amendments as at 29 October 2007

Amendment PaperLords

29 Oct 2007

Parliamentary Votes (0)

No recorded votes for this bill yet.